Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2026, Vol. 31 ›› Issue (10): 1410-1416.doi: 10.12092/j.issn.1009-2501.2026.10.012

Previous Articles    

Research progress on dotinurad in the treatment of hyperuricemia and gout

Yuanyuan ZHENG1,2(), Yulu BU1,2, Huizhen WU1,2,*()   

  1. 1. Graduate School, Hebei Medical University, Shijiazhuang 050017, Hebei, China
    2. Department of Pharmacy, Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacology, Shijiazhuang 050051, Hebei, China
  • Received:2025-08-19 Revised:2025-09-27 Online:2026-10-26 Published:2026-11-11
  • Contact: Huizhen WU E-mail:ZhengYY_HBMU@163.com;13582005982@163.com

Abstract:

Hyperuricemia, a metabolic disorder syndrome caused by dysregulation of purine metabolism, exhibits a significantly rising prevalence rate in China and has become a major public health concern. Currently available urate-lowering drugs face limitations in safety profiles, necessitating novel therapeutic options. Dotinurad, as a new-generation selective inhibitor of uric acid reabsorption, exerts its therapeutic effect by precisely targeting the urate transporter 1 (URAT1) on the apical membrane of renal proximal tubules. Its molecular mechanism involves the selective inhibition of the URAT1-mediated uric acid Cl-/organic anion exchange reabsorption pathway, thereby promoting uric acid excretion. This agent possesses pharmacokinetic characteristics including low volume of distribution and high plasma protein binding, ensuring long-lasting stable blood concentrations. It is primarily metabolized via glucuronidation/sulfation conjugation. Dosage adjustment is not required for patients with mild-to-moderate hepatic or renal impairment. Age and sex differences do not significantly affect its pharmacokinetics, and it carries a low risk of drug-drug interactions. This article reviews the fundamental profile, pharmacological research, clinical efficacy, and safety of dotinurad, aiming to provide expanded perspectives and alternatives for managing hyperuricemia with gout.

Key words: dotinurad, SURI, URAT1, hyperuricemia, gout

CLC Number: